In today’s cbd health news, learn more about FDA exploring the use of cannabis in food and dietary supplements to determine what public regulations are necessary. Meanwhile, an Italian study reveals that topical cannabidiol may promote the healing of digital ulcers, enhance quality of life, and reduce discomfort in patients with systemic sclerosis (SSc). Lastly, Experts at Levin Health Explain the Difference Between CBD and THC, the two most prominent cannabinoids found in the cannabis plant.
CBD in Foods, Supplements May Be Regulated by FDA
Original Source: FDA Explores Regulating CBD in Foods, Supplements
Cannabis in food and supplements is being studied by the FDA.
The FDA plans to issue health guidelines for cannabis product management in the coming months.
We want to make it clear that CBD findings indicate genuine hazards. “Risks include liver injury, harm to the male reproductive system, and side effects, such as changes in alertness and other symptoms,” Kristi Muldoon-Jacobs, Deputy Office Director, Office of Food Additive Safety, told the FDA.
The FDA is studying cannabis and CBD’s effects on pregnancy and fertility.
In 2018, Congress legalized hemp. It left hemp regulation to the FDA. Some states have cannabis laws, but CBD oil manufacturers have released products without guidelines.
CBD is abundant in hemp. THC and CBD are comparable, however CBD doesn’t intoxicate the brain and body like THC.
The FDA warns that CBD may interact with other drugs. Some antidepressants and painkillers lose efficacy when used with CBD.
Cannabis-derived goods are still considered medicines by the FDA. Except for severe seizure disorders in patients two years old and older, the government has not authorized cannabis companies to promote their medicines.
When used under medical supervision, Epidiolex’s advantages outweigh its hazards for its intended users.
Clinical trials are required for cannabis companies to claim therapeutic advantages.
However, the industry is still growing significantly. According to a cannabis statistics business, global cannabis sales might reach $57 billion by 2026 from $30 billion in 2021.
The National Institutes of Health say cannabinoid research is early. CBD may be dangerous to certain people, yet cannabis products may help relieve pain.
The FDA will regulate legal cannabis products after reviewing further research. Some regulations may require new laws from Congress.
Medicines, medical gadgets, dietary supplements, and food like baby formula are regulated by the FDA. Tobacco production, sales, and marketing are now under scrutiny by the FDA.
New cannabis substances like Delta-8, which has been on the market for years, complicate the agency’s studies, officials say. Unlike CBD, the new cannabinoid is intoxicating.
Muldoon-Jacobs said, “Data on CBD points to real risks, and the FDA is especially concerned about the risks to children, people who are pregnant or breastfeeding, and people taking other medications. Consumers should be aware of the risks and should speak with a medical provider about the use of any CBD product. We want people to make educated health decisions.”
Topical CBD May Help SSc Digital Ulcers, Study Finds
In systemic sclerosis (SSc) patients, topical cannabidiol may safely treat digital ulcers and enhance quality of life.
The therapy also improved nighttime sleep.
Advances in Skin & Wound Care published “Topical Cannabidiol in the Treatment of Digital Ulcers in Patients with Scleroderma: Comparative Analysis and Literature Review.”
Cannabis plant’s non-psychoactive component is in topical cannabidiol.
SSc patients’ digital ulcers are painful and difficult to cure, lowering quality of life.
Standard treatments like nonsteroidal anti-inflammatory drugs and opioids often don’t work or have negative effects. In SSc patients, many topically administered medications have been explored. It’s unknown if they work.
Topical CBD was tested for treating digital ulcers in SSc patients at the University Hospital of Modena. In recent years, CBD, a non-psychoactive cannabis component, has garnered scientific attention.
45 SSc patients (40 women) were examined, with a mean age of 53 years and a mean disease duration of 10.68 years. The majority of patients (35) had restricted scleroderma, while 10 had diffuse.
Opioid-resistant digital ulcers plagued the patients. According to the patient’s clinical condition and co-existing conditions, Ventavis (iloprost), calcium-channel blockers, Revatio (sildenafil), Tracleer (bosentan), or Opsumit (macitentan) were administered locally and systemically (e.g. pulmonary arterial hypertension).
Advanced dressings and surgical debridement were also used to treat wounds.
25 participants were randomly assigned to the CBD or control group (20). In the CBD group, high-quality pharmaceutical Cannabis sativa seed oil was applied to the lesion and surrounding skin. Four drops of oil were administered daily for up to two months over the clean incision and covered with nonadhesive gauze.
This pilot report suggests that CBD oil may be a useful topical treatment for SSc [digital ulcers] with no significant side effects and few mild side effects.
Topical cannabidiol greatly reduced pain.
One month of treatment reduced wound-related pain scores from 8.4 to 6. Volitional event pain, caused by voluntary actions like dressing and cleaning or treatment procedures, decreased from 9.32 to 6.8. The control group’s wound pain decreased from 8.44 to 7.88, which was not statistically significant, while volitional incident pain remained consistent.
Four participants in the CBD group needed acetaminophen, two needed it with codeine, four needed oxycodone, and four needed morphine (two). Analgesics were needed by all control group individuals.
The CBD group’s mean nighttime sleep hours increased from 2.56 to 5.67. The Health Assessment Questionnaire Disability Index, a self-measure of daily life activities, reduced from 2.19 to 0.79 at follow-up, indicating improved quality of life. These factors did not change for the control group.
CBD group had more wound healing.
18 CBD-treated subjects (72%) healed their digital ulcers, compared to six (30%) in the control group. In contrast, six patients in the control group needed antibiotics for wound infections.
There were no notable adverse occurrences. No patient had severe negative effects from treatment. Seven CBD users (28%) experienced moderate side effects as itchiness and wound redness. CBD was not withdrawn.
The researchers wrote that “the present study is the first to report the effectiveness of local CBD treatment in the management of SSc-DUs [digital ulcers],” adding that “the results of this preliminary report encourage further exploration of CBD oil as a potentially helpful topical treatment in the management of SSc-DUs, having no major adverse effects and few minor adverse effects.”
Levin Health Experts Explain CBD and THC
Original Source: Experts at Levin Health Explain the Difference Between CBD and THC
January 14, 2023, Melbourne, Australia (GLOBE NEWSWIRE) Delta-9-tetrahydrocannabinol (THC) and cannabidiol are among the 80-100 cannabinoids in cannabis sativa (CBD). Cannabinoids control mood, memory, sleep, and hunger through interacting with the body’s endocannabinoid system.
The distinction between the two cannabinoids is explained by Levin Health, an Australian sports science firm that researches, develops, and sells therapeutic cannabis products like CBD oil nationwide.
THC and CBD have the same chemical makeup but different chemical arrangements. Because of this, the body gets them as various molecules, which affects their effectiveness and side effects.
THC is usually associated with recreational marijuana usage, which is currently banned in Australia. Psychoactive effects come from this cannabinoid. This gives consumers a “high.”
According to Levin Health, CBD-dominant drugs are less likely to cause psychoactivity. Although CBD doesn’t include THC, CBD products may contain trace levels that won’t get you high.
In a CBD-dominated medicinal cannabis Melbourne and Australia study, anxiety was one of the top three causes for a prescription. Dr. Elizabeth Cairns from The University of Sydney says, “Historically, the effects of THC have been described as anxiety-inducing, but this may depend on dose size and other circumstances.”
Medical marijuana in Australia is primarily THC and CBD, according to Levin Health. Since they’re the two most studied cannabinoids, we know how much THC or CBD may work for a certain ailment.
High-CBD medical cannabis products have less adverse effects than high-THC ones, according to Levin Health. However, taking CBD with other pharmaceuticals or medications can modify its benefits and induce undesirable side effects.
Medicinal cannabis products can produce dizziness, nausea, sleepiness, and difficulties concentrating, just like prescription drugs.
Summary of today’s CBD Health News
Overall, the FDA is now investigating the use of cannabis in food and dietary supplements to ascertain its safety. The Food and Drug Administration plans to release health recommendations in the coming months to address the proliferation of cannabis products, according to agency officials. “We want to make it apparent that there are significant hazards that should be evaluated based on the facts on CBD. Kristi Muldoon-Jacobs, Deputy Office Director, Office of Food Additive Safety, warned the FDA in a study that there are risks, including liver injury, impairment to the male reproductive system, and side effects include changes in alertness and other symptoms.
Meanwhile, an Italian study found that cannabidiol used topically helped speed up the recovery time for digital ulcers, increased quality of life, and reduced discomfort in persons with systemic sclerosis (SSc). Those who received the treatment also slept longer and more soundly each night.
Finally, cannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC) are the most well-known. According to Levin Health, they have different chemical compositions, different risks, and different “high” effects.